Kampmann Melissa S. Has $3.36 Million Stake in Johnson & Johnson $JNJ

Kampmann Melissa S. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,984 shares of the company’s stock after selling 370 shares during the quarter. Johnson & Johnson makes up about 2.5% of Kampmann Melissa S.’s investment portfolio, making the stock its 19th biggest holding. Kampmann Melissa S.’s holdings in Johnson & Johnson were worth $3,358,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new stake in Johnson & Johnson during the first quarter worth $218,000. GAMMA Investing LLC raised its position in Johnson & Johnson by 48.0% during the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after acquiring an additional 14,118 shares in the last quarter. Davis Investment Partners LLC raised its position in Johnson & Johnson by 7.9% during the first quarter. Davis Investment Partners LLC now owns 4,429 shares of the company’s stock worth $682,000 after acquiring an additional 326 shares in the last quarter. Finally, Yarger Wealth Strategies LLC raised its position in Johnson & Johnson by 6.2% during the first quarter. Yarger Wealth Strategies LLC now owns 1,560 shares of the company’s stock worth $259,000 after acquiring an additional 91 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. HSBC raised their target price on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Finally, Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $192.94.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.2%

Shares of Johnson & Johnson stock opened at $190.66 on Friday. The firm has a market capitalization of $459.16 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm’s 50 day moving average is $178.48 and its 200 day moving average is $163.76. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $24.02 billion for the quarter. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.